Last reviewed · How we verify
Epi 200
At a glance
| Generic name | Epi 200 |
|---|---|
| Also known as | epinephrine |
| Sponsor | Seoul Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness (EARLY_PHASE1)
- The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease (NA)
- Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP) (PHASE4)
- Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) (PHASE4)
- Evaluating Postoperative Pain and Antibacterial Effect of Ultrasonic and 980 nm Diode Laser Combination (NA)
- Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) (PHASE3)
- A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations (PHASE2)
- Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epi 200 CI brief — competitive landscape report
- Epi 200 updates RSS · CI watch RSS
- Seoul Medical Center portfolio CI